Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637662 | 0.85 | AKR1C1 (0.47) | AKR1C1ALDH1A1TSHRLMNALDHA | |
| SCHEMBL4637584 | 0.85 | AKR1C1 (0.47) | AKR1C1ALDH1A1TSHRLMNALDHA | |
| SCHEMBL487380 | 0.85 | AKR1C1 (0.47) | AKR1C1ALDH1A1TSHRLMNALDHA | |
| SCHEMBL5665997 | 0.84 | AKR1C1 (0.40) | AKR1C1ALDH1A1SMN1; SMN2TSHRLMNA | |
| Ammonia Solution, Strong SCHEMBL6650400 | 0.83 | AKR1C1 (0.45) | AKR1C1ALDH1A1TSHRLMNALDHA | |
| SCHEMBL11303680 | 0.79 | OPRM1 (0.47) | ALDH1A1SMN1; SMN2NPSR1GAAOPRM1 | |
| SCHEMBL4829823 | 0.76 | AKR1C1 (0.48) | AKR1C1ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL10848298 | 0.75 | AKR1C1 (0.52) | AKR1C1ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL29240149 | 0.72 | HTR2A (0.41) | AKR1C1ALDH1A1TSHRLMNALDHA | |
| Potassium Ion SCHEMBL11295824 | 0.72 | AKR1C1 (0.38) | AKR1C1SMN1; SMN2TSHRLMNALDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1085909-B1 | A complex of alpha-fetoprotein (AFP) and a polyunsaturated fatty acid derivative for the treatment of immune deficiencies | ARDENIA INVESTMENTS LTD (GI) | 2005-12-28 | — | — | EP | disclosed |
| US-6599507-B2 | Immunostimulation | ARDENIA INVESTMENTS, LTD. (GI) | 2003-07-29 | — | — | US | disclosed |
| US-20010034324-A1 | Composition for the treatment of immune deficiencies and methods for its preparation and use | OASMIA PHARMACEUTICAL AB (SE) | 2001-10-25 | — | — | US | disclosed |
| EP-1085909-A2 | COMPOSITION FOR THE TREATEMENT OF IMMUNE DEFICIENCIES AND METHODS FOR ITS PREPARATION AND USE | Ardenia Investments Ltd. (GI) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065936-A2 | COMPOSITION FOR THE TREATEMENT OF IMMUNE DEFICIENCIES AND METHODS FOR ITS PREPARATION AND USE | ARDENIA INVESTMENTS LTD. (GI) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034324-A1 | Composition for the treatment of immune deficiencies and methods for its preparation and use | ALB, NAPEPLD, TTPA | AKR1C1 3429/4885ALDH1A1 2119/4885HTR1A 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.